Background Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival. Methods This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly assigned patients with HER2-positive early breast cancer, aged 18 years or older, and with a clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either ...
BACKGROUND: Trastuzumab improves survival in HER2+ breast cancer patients, with some evidence of adv...
In the 1980s, HER2 overexpressing tumors were recognized as a distinct subset of breast cancer, with...
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to ...
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
Background The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes ...
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcome...
This is the author accepted manuscript.The final version is available from Elsevier via the DOI in t...
This is the final version. Available on open access from the NIHR Journals Library via the DOI in th...
Adjuvant trastuzumab for patients with HER2 positive early breast cancer demonstrated significant im...
Background: Twelve months treatment is the current standard of care for adjuvant trastuzumab in pati...
Adjuvant trastuzumab for patients with HER2-positive early breast cancer showed significant improvem...
IMPORTANCE Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human ...
Among breast cancers diagnosed at any stage, 20%\u201330% are found to have HER2 gene amplification/...
BACKGROUND: Trastuzumab improves survival in HER2+ breast cancer patients, with some evidence of adv...
In the 1980s, HER2 overexpressing tumors were recognized as a distinct subset of breast cancer, with...
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to ...
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive ear...
Background The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes ...
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcome...
This is the author accepted manuscript.The final version is available from Elsevier via the DOI in t...
This is the final version. Available on open access from the NIHR Journals Library via the DOI in th...
Adjuvant trastuzumab for patients with HER2 positive early breast cancer demonstrated significant im...
Background: Twelve months treatment is the current standard of care for adjuvant trastuzumab in pati...
Adjuvant trastuzumab for patients with HER2-positive early breast cancer showed significant improvem...
IMPORTANCE Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human ...
Among breast cancers diagnosed at any stage, 20%\u201330% are found to have HER2 gene amplification/...
BACKGROUND: Trastuzumab improves survival in HER2+ breast cancer patients, with some evidence of adv...
In the 1980s, HER2 overexpressing tumors were recognized as a distinct subset of breast cancer, with...
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to ...